
    
      This is a phase 1, randomized, double-blind, placebo-controlled, dose-escalation study to
      evaluate the safety, tolerability and pharmacokinetics of MEDI4893, an extended half-life
      human monoclonal antibody against Staphylococcus aureus alpha toxin, in healthy adult
      subjects. Approximately 33 subjects will be enrolled across 4 fixed dose cohorts at 1 study
      site . This study will last approximately 389 days, constituting a screening period of up to
      28 days, 1 day of investigational product administration, and a 360 day safety follow up
      period.
    
  